KCNA3 and metabolic syndrome: Notably, Kv1.3 inhibitors demonstrate increased efficacy in preventing restenosis in human T2DM vessels and in a mouse model of metabolic syndrome and T2DM (Arevalo-Martinez et al., 2021).